<DOC>
	<DOC>NCT00189306</DOC>
	<brief_summary>An open-label study to evaluate the safety and the ability of Imiquimod 5% cream, applied topically, to clear superficial basal cell carcinoma and to keep it clear for 5 years of follow-up.</brief_summary>
	<brief_title>Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream</brief_title>
	<detailed_description>Evaluate the long-term sustained clearance rate, defined as the proportion of those subjects clinically clear of basal cell carcinoma (BCC) at the treated superficial BCC (sBCC) target tumor site at the 12-week posttreatment visit who remain clear during a 5 year follow-up period.</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Basal Cell</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Have at least 1 previously untreated superficial basal cell carcinoma tumor Minimum tumor size 0.5 cm2 and maximum diameter of 2.0 cm Evidence of clinically significant, unstable medical conditions Cannot have recent use of topical steroids or retinoids in the treatment area.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Superficial Basal Cell Carcinoma</keyword>
	<keyword>Aldara</keyword>
</DOC>